RPS6KB2 and chronic myelogenous leukemia, BCR-ABL1 positive: To further explore this finding, we returned to our mouse model and compared dipeptide levels in CML-KLS+ cells isolated from CML-affected mice that had received vehicle or IM therapy for 1 month.